retatrutide clinical trials countries of subcutaneous tirzepatide, retatrutide, and State of the evidence: a

TL;DR What This Analysis Covers This isn't a ranking

These drugs act on brain pathways involved in appetite regulation and reward

Retatrutide is still years away from FDA approval, but the drug has entered a new phase of its life cycle

They act on receptors in the brain and digestive system that control appetite, fullness, and blood sugar

Track Your Symptoms: Keep a simple log for the first month

Patients must be at least 18 years old and meet one of the following clinical requirements when GLP-1 therapy begins: A body mass index, or BMI, of 35 or higher A BMI between 30 and 34.99 with at least one qualifying health condition A BMI between 27 and 29.99 with at least one qualifying higher-risk health condition For someone with a BMI between 30 and 34.99, qualifying conditions may include heart failure with preserved ejection fraction, uncontrolled high blood pressure, stage 3a or higher chronic kidney disease, prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease